Most Read

HBM7022 has been produced from HBM’s HCAb Based Immune Cell Engagers (HBICE) Platform. It crosslinks tumour and T cells by targeting a tumour-associated antigen (Claudin18.2) and CD3 that

A kinase inhibitor, vijoice is intended for the treatment of rare overgrowth conditions which are caused by the effects of PIK3CA mutations in adults and children aged two

Upon receiving approval, the human monoclonal antibody Dupixent will be the first medicine available in the US for the treatment of eosinophilic esophagitis (EoE). It is designed to

A recombinant humanized IgG4 monoclonal antibody, TAB009/JS009 is developed against human CD112R to treat advanced malignant tumours. CD112R, also known as Poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG), is

Under the deal, Organon will obtain global rights to FDA-approved Xaciato, which is intended to treat bacterial vaginosis (BV) in females aged 12 years and above. The vaginal

The company filed the NDA with the Department of Health in the Hong Kong Special Administrative Region. The SG drug is a first-in-class Trop-2 directed antibody-drug conjugate and

The first-in-class bio-HDL mimetic CER-001 works by directly targeting a key underlying metabolic defect of LCAT deficiency. Its anti-inflammatory properties and/or the increase in the Reverse Cholesterol Transport

Under the terms of the deal, Axsome will gain global development, manufacturing commercial, and intellectual property rights to Sunosi, a dual-acting dopamine and norepinephrine reuptake inhibitor, except for

The regulator has also granted paediatric exclusivity for the prescription medication. It was previously approved by the FDA and EU Commission to treat Dravet syndrome-related seizures in children